A citation-based method for searching scientific literature

Anurag Mehta, Ajita Verma, Garima Gupta, Rupal Tripathi, Anurag Sharma. Indian J Hematol Blood Transfus 2020
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
661
100

ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Grzegorz S Nowakowski, Myron S Czuczman. Am Soc Clin Oncol Educ Book 2015
71
100

Distribution of Ki67 proliferative indices among WHO subtypes of non-Hodgkin's lymphoma: association with other clinical parameters.
Atif Ali Hashmi, Zubaida Fida Hussain, Naveen Faridi, Amna Khurshid. Asian Pac J Cancer Prev 2014
16
50


MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Briere, Richard Delarue, Danielle Canioni, Gilles Salles, Marie Parrens, Karim Belhadj, Bettina Fabiani,[...]. Blood 2015
155
50

The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
Maria Naseem, Muhammad Asif, Muhammad Tahir Khadim, Hafeez Ud-Din, Shahid Jamal, Iman Shoaib. Asian Pac J Cancer Prev 2020
3
50

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.
Ting-Xun Lu, Lei Fan, Li Wang, Jia-Zhu Wu, Kou-Rong Miao, Jin-Hua Liang, Qi-Xing Gong, Zhen Wang, Ken H Young, Wei Xu,[...]. Oncotarget 2015
42
50


Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
482
50

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Qing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, Lijuan Deng, Xiaoxiao Wang, Ganiraju C Manyam, Carlo Visco, Santiago Montes-Moreno, Li Zhang, Karen Dybkær,[...]. Oncotarget 2016
70
50

Diffuse large B-cell lymphoma.
Shaoying Li, Ken H Young, L Jeffrey Medeiros. Pathology 2018
257
50

How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
Christian Gisselbrecht, Eric Van Den Neste. Br J Haematol 2018
89
50

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane,[...]. Ann Oncol 2018
77
50

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
50

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Ujjawal H Gandhi, William Senapedis, Erkan Baloglu, Thaddeus J Unger, Ajai Chari, Dan Vogl, Robert F Cornell. Clin Lymphoma Myeloma Leuk 2018
65
50


Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
50

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Kai Fu, Dennis D Weisenburger, William W L Choi, Kyle D Perry, Lynette M Smith, Xinlan Shi, Christine P Hans, Timothy C Greiner, Philip J Bierman, R Gregory Bociek,[...]. J Clin Oncol 2008
252
50

Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Joel G Turner, Douglas C Marchion, Jana L Dawson, Michael F Emmons, Lori A Hazlehurst, Peter Washausen, Daniel M Sullivan. Cancer Res 2009
62
50

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
50

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
H Tilly, M Gomes da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, J Walewski, M André, P W Johnson, M Pfreundschuh,[...]. Ann Oncol 2015
434
50

Diffuse Large B-Cell Lymphoma.
Laurie H Sehn, Gilles Salles. N Engl J Med 2021
117
50

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin,[...]. Lancet 2020
107
50

Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
Solomon A Graf, Ryan D Cassaday, Karolyn Morris, Jenna M Voutsinas, Qian Vicky Wu, Sanaz Behnia, Ryan C Lynch, Elizabeth Krakow, Heather Rasmussen, Thomas R Chauncey,[...]. Clin Lymphoma Myeloma Leuk 2021
5
50

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
M Wang, N Fowler, N Wagner-Bartak, L Feng, J Romaguera, S S Neelapu, F Hagemeister, M Fanale, Y Oki, B Pro,[...]. Leukemia 2013
158
50

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Myron S Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M Linton, Nina Wagner-Johnston, Randy D Gascoyne, Graham W Slack, Pierre Brousset, David A Eberhard,[...]. Clin Cancer Res 2017
108
50

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Andreas Rosenwald, George Wright, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Randy D Gascoyne, H Konrad Muller-Hermelink, Erlend B Smeland, Jena M Giltnane,[...]. N Engl J Med 2002
50

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Alex F Herrera, Matthew Mei, Lawrence Low, Haesook T Kim, Gabriel K Griffin, Joo Y Song, Reid W Merryman, Victoria Bedell, Christine Pak, Heather Sun,[...]. J Clin Oncol 2017
113
50

Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Ichiro Kawashima, Yoshihiro Inamoto, Akiko Miyagi Maeshima, Junko Nomoto, Kinuko Tajima, Tadahiro Honda, Takafumi Shichijo, Akihisa Kawajiri, Tomonari Takemura, Akio Onishi,[...]. Biol Blood Marrow Transplant 2018
14
50

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S P Vermaat, Olivier Casasnovas, Nada Hamad, Josée M Zijlstra, Sameer Bakhshi,[...]. Lancet Haematol 2020
123
50

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
50


Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Paul N Meyer, Kai Fu, Timothy C Greiner, Lynette M Smith, Jan Delabie, Randy D Gascoyne, German Ott, Andreas Rosenwald, Rita M Braziel, Elias Campo,[...]. J Clin Oncol 2011
343
50

Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Julie M Vose, Thomas M Habermann, Myron S Czuczman, Pier Luigi Zinzani, Craig B Reeder, Joseph M Tuscano, Izidore S Lossos, Ju Li, Dennis Pietronigro, Thomas E Witzig. Br J Haematol 2013
31
50

nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.
Ali G Saad, Zakaria Grada, Barbara Bishop, Hend Abulsayen, Mohamed Hassan, Adolfo Firpo-Betancourt, Julie Teruya-Feldstein, Mostafa Fraig, Siraj M El Jamal. Appl Immunohistochem Mol Morphol 2019
6
50

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
Y-T Tai, Y Landesman, C Acharya, Y Calle, M Y Zhong, M Cea, D Tannenbaum, A Cagnetta, M Reagan, A A Munshi,[...]. Leukemia 2014
206
50

Management of relapsed/refractory DLBCL.
Clémentine Sarkozy, Laurie H Sehn. Best Pract Res Clin Haematol 2018
59
50

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
J Schmidt, E Braggio, K M Kortuem, J B Egan, Y X Zhu, C S Xin, R E Tiedemann, S E Palmer, V M Garbitt, D McCauley,[...]. Leukemia 2013
121
50

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
936
50

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.
Joel G Turner, Jana Dawson, Michael F Emmons, Christopher L Cubitt, Michael Kauffman, Sharon Shacham, Lori A Hazlehurst, Daniel M Sullivan. J Cancer 2013
53
50

Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues.
Wan-Hui Yan, Xiang-Nan Jiang, Wei-Ge Wang, Yi-Feng Sun, Yi-Xin Wo, Zheng-Zhi Luo, Qing-Hua Xu, Xiao-Yan Zhou, Jun-Ning Cao, Xiao-Nan Hong,[...]. Front Oncol 2020
7
50

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.
Allison M Winter, Daniel J Landsburg, Anthony R Mato, Krista Isaac, Francisco J Hernandez-Ilizaliturri, Nishitha Reddy, Stephen Smith, Mazyar Shadman, Mitchell R Smith, Paolo Caimi,[...]. Blood 2017
22
50

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
Daniel J Landsburg, Mitchell E Hughes, Alexa Koike, David Bond, Kami J Maddocks, Ling Guo, Allison M Winter, Brian T Hill, Sarah L Ondrejka, Eric D Hsi,[...]. Blood Adv 2019
10
50

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
50

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
David W Scott, Rebecca L King, Annette M Staiger, Susana Ben-Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W Slack, Daisuke Ennishi,[...]. Blood 2018
109
50

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Nara Yoon, Soomin Ahn, Hae Yong Yoo, Suk Jin Kim, Won Seog Kim, Young Hyeh Ko. Oncotarget 2017
30
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.